V. Runza

发表

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Y. Kienast, C. Ries, O. Ast, 2018, The Journal of experimental medicine.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

P. Paschka, G. Martinelli, W. Fiedler, 2016, Oncotarget.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

J. Blay, F. Feuerhake, A. Sica, 2014, Cancer cell.

Screening of Catalytically Active Microorganisms for the Synthesis of 6-Modified Purine Nucleosides

A. Iribarren, E. Lewkowicz, V. Runza, 2005, Biotechnology Letters.

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal

Richard A. Moore, Christian L. Barrett, K. Frazer, 2015, Proceedings of the National Academy of Sciences.

Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004))

S. Bicciato, J. Galon, C. Ries, 2016 .

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Fabian Birzele, E. Voss, H. Verheul, 2015, Clinical Cancer Research.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.

A drug development perspective on targeting tumor‐associated myeloid cells

C. Ries, M. Majety, S. Hoves, 2018, The FEBS journal.

Localization of the mouse defense lectin ficolin B in lysosomes of activated macrophages

B. Echtenacher, D. Männel, U. Zähringer, 2006, Journal of Endotoxin Research.

Ficolins: novel pattern recognition molecules of the innate immune response.

D. Männel, W. Schwaeble, V. Runza, 2008, Immunobiology.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

C. Klein, B. Liu, K. Packman, 2016, Molecular Cancer Therapeutics.

Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model

E. Voss, D. Maisel, D. Laifenfeld, 2016, PloS one.

Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B.

D. Männel, P. Elumalai, D. Schmidt, 2013, Molecular immunology.

Functional analysis of mouse ficolin-B and detection in neutrophils.

J. Jensenius, D. Männel, V. Runza, 2012, Immunobiology.

End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations

M. Bader, T. Schlothauer, K. Bray-French, 2023, International journal of pharmaceutics: X.

Localization of the mouse defense lectin ficolin B in lysosomes of activated macrophages.

B. Echtenacher, D. Männel, U. Zähringer, 2006 .

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

J. Blay, F. Feuerhake, A. Sica, 2014, Cancer cell.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.